{"id":688658,"date":"2022-09-26T07:33:29","date_gmt":"2022-09-26T11:33:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/"},"modified":"2022-09-26T07:33:29","modified_gmt":"2022-09-26T11:33:29","slug":"intellia-therapeutics-to-present-at-october-healthcare-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/","title":{"rendered":"Intellia Therapeutics to Present at October Healthcare Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Sept.  26, 2022  (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October:<\/p>\n<p>\n        <strong>Chardan\u2019s 6th Annual Genetic Medicines Conference, New York<\/strong><br \/>\n        <br \/>Date: Monday, October 3, 2022<br \/>Time: 8:30 a.m. ET<br \/>Format: Fireside chat<\/p>\n<p>\n        <strong>2022 Truist Securities Genetic Medicine Summit, New York<\/strong><br \/>\n        <br \/>Genome Editing Panel <br \/>Date: Thursday, October 20, 2022<br \/>Time: 9:00 a.m. ET<br \/>Format: Panel discussion<\/p>\n<p>A live webcast of Intellia\u2019s fireside chat at the Chardan conference will be accessible through the Events and Presentations page of the Investors &amp; Media section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zdldeFT-ubzwJD80-7zz7acwoCde_aPErVIeU1_xDrOV7JFJwEUX2nEApIgW6gfRVP1XfpmfgzKBQxS1jdVQT_58Ndolt1EJng8aVAE9wVA=\" rel=\"nofollow noopener\" target=\"_blank\">www.intelliatx.com<\/a>. Replay of the webcast will be available on Intellia\u2019s website for at least 30 days following the presentation.<\/p>\n<p>\n        <strong>About Intellia Therapeutics<\/strong><br \/>\n        <br \/>Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company\u2019s <em>in vivo<\/em> programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia\u2019s <em>ex vivo<\/em> programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia\u2019s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L__y0qX_i-D-8e5wMRF5lUqFWPK_BJWwMGs5Le7Z6SpJpcfEzY7cKj5aGhJxFmROzsy5C3KlZDAjVaVuh6ONUP0SK3ODGmLb4pO-jIg91qBvyfxTBT3XCoReJL3aDrmu_59h2Rg17Ycx_8xfFLpgftxc1mutizijgF0BYeSGY6ddaWTrhbVzkcyF2ZoKaSBK8H4B3LJgcbOKHJvZSDWPBfEFTLYuoz3smraOgKPwd5w=\" rel=\"nofollow noopener\" target=\"_blank\"><u>intelliatx.com<\/u><\/a>. Follow us on Twitter\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WM6q7f1VH3tcXmxYbDBS5ZJZUi6pJitE3QvzR5WdGlVunsy2u0l7KX38YPUjw0-wt38EPIGzqiUS8GCi9doWsw==\" rel=\"nofollow noopener\" target=\"_blank\">@intelliatx<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>Intellia Contacts:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Ian Karp<br \/>Senior Vice President, Investor Relations and Corporate Communications<br \/>+1-857-449-4175<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UU6-EYeJUpzefiAOJXNH3yLtjFdHbwcLdE3mEHacYAazWCAPwWXvItyA3jr_8Z_RuzALUK5wYhEkVczHb8Si1KZUX6AFJ7RxLSHNDz5MsoQ=\" rel=\"nofollow noopener\" target=\"_blank\">ian.karp@intelliatx.com<\/a><\/p>\n<p>Lina Li<br \/>Senior Director, Investor Relations and Corporate Communications <br \/>+1-857-706-1612<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rOCcbWyJynluQ5dg3GbiDmUzmVQajLg-qNj26zdIri3ta9ZiwBLsuJWvIcNO4XQYlegxVthlN_ABqVMhl3OENHt92X46GKvaJllcFvwboDg=\" rel=\"nofollow noopener\" target=\"_blank\">lina.li@intelliatx.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MDgxMWZiNzctYWY4Mi00NGNiLWJmNzctYTdlMDZkMTA2ODU5LTEwNDA3NzI=\/tiny\/Intellia-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October: Chardan\u2019s 6th Annual Genetic Medicines Conference, New York Date: Monday, October 3, 2022Time: 8:30 a.m. ETFormat: Fireside chat 2022 Truist Securities Genetic Medicine Summit, New York Genome Editing Panel Date: Thursday, October 20, 2022Time: 9:00 a.m. ETFormat: Panel discussion A live webcast of Intellia\u2019s fireside chat at the Chardan conference will be accessible through the Events and Presentations page of the Investors &amp; Media section of the company\u2019s website at www.intelliatx.com. Replay of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Intellia Therapeutics to Present at October Healthcare Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688658","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Intellia Therapeutics to Present at October Healthcare Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics to Present at October Healthcare Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October: Chardan\u2019s 6th Annual Genetic Medicines Conference, New York Date: Monday, October 3, 2022Time: 8:30 a.m. ETFormat: Fireside chat 2022 Truist Securities Genetic Medicine Summit, New York Genome Editing Panel Date: Thursday, October 20, 2022Time: 9:00 a.m. ETFormat: Panel discussion A live webcast of Intellia\u2019s fireside chat at the Chardan conference will be accessible through the Events and Presentations page of the Investors &amp; Media section of the company\u2019s website at www.intelliatx.com. Replay of the &hellip; Continue reading &quot;Intellia Therapeutics to Present at October Healthcare Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-26T11:33:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intellia Therapeutics to Present at October Healthcare Investor Conferences\",\"datePublished\":\"2022-09-26T11:33:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/\"},\"wordCount\":316,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/\",\"name\":\"Intellia Therapeutics to Present at October Healthcare Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=\",\"datePublished\":\"2022-09-26T11:33:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics to Present at October Healthcare Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics to Present at October Healthcare Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Intellia Therapeutics to Present at October Healthcare Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October: Chardan\u2019s 6th Annual Genetic Medicines Conference, New York Date: Monday, October 3, 2022Time: 8:30 a.m. ETFormat: Fireside chat 2022 Truist Securities Genetic Medicine Summit, New York Genome Editing Panel Date: Thursday, October 20, 2022Time: 9:00 a.m. ETFormat: Panel discussion A live webcast of Intellia\u2019s fireside chat at the Chardan conference will be accessible through the Events and Presentations page of the Investors &amp; Media section of the company\u2019s website at www.intelliatx.com. Replay of the &hellip; Continue reading \"Intellia Therapeutics to Present at October Healthcare Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-26T11:33:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intellia Therapeutics to Present at October Healthcare Investor Conferences","datePublished":"2022-09-26T11:33:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/"},"wordCount":316,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/","name":"Intellia Therapeutics to Present at October Healthcare Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=","datePublished":"2022-09-26T11:33:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU5MiM1MTY5Njc4IzIwMjkyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-present-at-october-healthcare-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics to Present at October Healthcare Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688658"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688658\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}